Loading stock data…
MGX
$1.23-0.06 (-4.65%)
After Hours$1.23+0.00 (+0.00%)· Last close Jun 9
Metagenomi Therapeutics, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Metagenomi Therapeutics, Inc. in the Healthcare sector is trading at $1.24 with a market capitalization of $50M. Wall Street consensus targets $8.00 (2 analysts), implying a +545.2% move over the next 12 months. The stock is currently near its 52-week low of $1.21, remaining 29.5% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +545.2% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$1.23
Potential Downside
0%
Whystock Fair Value$1.23
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States. The company's lead development program, MGX-001, is designed to provide curative, life-long protection from bleeding events and...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$50.07M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-62.33%
Volume
Today's trading volume
173,854
Recent News
Metagenomi Therapeutics, Inc. (NASDAQ:MGX) Just Reported And Analysts Have Been Cutting Their Estimates
Metagenomi Therapeutics, Inc. ( NASDAQ:MGX ) missed earnings with its latest first-quarter results, disappointing...
Metagenomi Therapeutics (MGX) Reports Q1 Loss, Misses Revenue Estimates
Metagenomi Therapeutics (MGX) delivered earnings and revenue surprises of -2.52% and -68.08%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Assembly Biosciences (ASMB) Reports Q1 Loss, Misses Revenue Estimates
Assembly Biosciences (ASMB) delivered earnings and revenue surprises of +26.03% and -10.73%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Spotlight On 3 ASX Penny Stocks With Market Caps Under A$2B
As Australian shares edge towards a 0.5% advance, buoyed by optimism around geopolitical developments in the Middle East, investors are turning their attention to the potential of penny stocks on the ASX. Although "penny stocks" may seem like an outdated term, they still represent an intriguing investment area for those looking to uncover opportunities in smaller or less-established companies. By focusing on firms with strong financials and growth potential, investors can find promising...
Metagenomi Therapeutics (MGX) Reports Q4 Loss, Misses Revenue Estimates
Metagenomi Therapeutics (MGX) delivered earnings and revenue surprises of -4.35% and -54.84%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?